SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is facing significant downward volatility as investors grapple with sector-wide selling pressure, ongoing dilution concerns, and intense debate over the company's operational execution. While some community members remain focused on the long-term potential of the Tanbreez project as a strategic Western asset, others are voicing frustration over delayed feasibility studies and retracted tender news, leading to heated discussions about the stock's valuation and management's transparency.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community prepares for a pivotal July 29th FDA advisory committee meeting regarding the approval of deramiocel for Duchenne muscular dystrophy. Investors are closely monitoring the potential for a dual-label approval and a significant short squeeze, while community discussions emphasize the drug's strong clinical data and the critical need for new treatment options.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors debate the stock's long-term valuation potential amid significant volatility, with the community closely tracking institutional accumulation patterns and the timeline for QNX design wins. While some investors remain bullish on its role in physical AI, robotics, and cybersecurity, others are voicing frustration over recent share price declines and limited communication from management regarding key growth catalysts.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is trending as investors weigh recent strategic pivotsincluding new partnerships with Chinese automakers and a renewed focus on affordable vehiclesagainst ongoing concerns about profitability, high inventory levels, and a challenging global automotive environment. The community is actively debating the company's long-term valuation, with many seeing deep-value potential in its current price levels, while others remain skeptical of management's ability to navigate execution risks and weakening consumer demand.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing significant market momentum and investor interest driven by positive interim data for its NXC-201 CAR-T therapy, which has demonstrated high complete response rates in relapsed/refractory AL amyloidosis. The community is actively discussing the company's strong clinical results, recent institutional accumulation, and the potential for a rerating following a new price target initiation from a major firm and ongoing expansion of its executive leadership team.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened market volatility driven by broader sector instability and speculative bankruptcy fears surrounding peers, leading investors to closely watch the stock's consolidation phase ahead of upcoming earnings. The community remains divided, with bulls pointing to robust R2 demand and production scaling, while bears express skepticism over sustained cash burn and competitive pressures.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is experiencing significant market interest driven by its role as a key supplier in the TSMC COUPE platform for co-packaged optics and expanding potential in AI-integrated hardware. The community remains focused on the company's evolving narrative from a display-chip provider to an AI and edge-compute participant, with ongoing discussions about institutional positioning, potential supply chain expansion, and expectations for sustained growth through 2028.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is trending as investors anticipate upcoming mid-year earnings and potential new widebody engine orders, while the community remains highly focused on the firm's expanding defense contracts and momentum in the Small Modular Reactor sector. Despite broader market volatility, discussions are heavily centered on management's turnaround strategy, sustained share buybacks, and the company's long-term positioning as a leader in autonomous defense technology.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is currently trending as investors monitor ongoing antitrust scrutiny and legal challenges, including a temporary pause on the Paramount-Skydance acquisition. The community is actively debating the potential long-term impacts of these regulatory delays, the significance of ticking fees, and the broader implications for media consolidation.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as investors weigh recent strategic shifts, including a research facility closure and new executive hires, against active buyout speculation following high-profile sector acquisitions. The community is focused on the tension between these structural moves and intense short-interest dynamics, with many debating whether the stock is a prime candidate for a near-term takeover or a long-term commercial play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally

Key Points4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share...

ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors

ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors PR Newswire BERKELEY, Calif., June 9, 2026 BERKELEY, Calif., June 9, 2026 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering a topical cell...

Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA

Jennison Associates LLC boosted its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 262.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387,483 shares of the company's stock after purchasing an additional...

Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-palvella-therapeutics-stock...

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the stock, Marketbeat reports...

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - What's Next?

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - Time to Buy...

Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA

Deltec Asset Management LLC decreased its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 80.8% in the 4th quarter, according to the company in its most recent filing with the...

Palvella Therapeutics (NASDAQ:PVLA) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen downgraded Palvella Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are covering the company, MarketBeat.com...

Lifesci Capital Brokers Decrease Earnings Estimates for PVLA

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Investment analysts at Lifesci Capital lowered their FY2026 earnings per share (EPS) estimates for Palvella Therapeutics in a note issued to...

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Palvella Therapeutics Inc.

Why Did PVLA Stock Surge 37% Today?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$138.01
Prev Close	$143.21
Open	$144.45
Dividend Yield	0.00%
50-Day Moving Average	$126.66
Beta	1.14
Avg. Volume	347,580.24
PE Ratio	-33.11

52-Week High	$161.38
52-Week Low	$34.57
Market Capitalization	$1.98B
EPS (Annual)	-$3.71
Price to Book	8.50
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PVLAPalvella Therapeutics Inc

Latest PVLA News